QualityStocks would like to highlight Echo Therapeutics (NASDAQ: ECTE). Echo Therapeutics is a transdermal medical device company with deep expertise in advanced skin permeation technology. Echo is developing its Prelude® SkinPrep System as a platform technology to allow for significantly enhanced and painless skin permeation that will enable two important applications: needle-free drug delivery and analyte extraction.
In the company’s news yesterday,
Echo Therapeutics Inc. announced positive results of a clinical study of its new and improved biosensor, the Symphony tCGM System, for patients with type 1 and type 2 Diabetes.
The Symphony tCGM System consists of the company’s wireless transmission and transdermal biosensor technologies, as well as its Prelude SkinPrep System, which incorporates needle-free, controlled skin ablation.
The study tested the performance of the system in glucose readings in ten patients with type 1 or type 2 Diabetes; results showed a 97 percent accuracy in the readings.
“This study represents another major step forward in our Symphony development program,” Patrick Mooney, M.D., Echo chairman and CEO stated in the press release. “We believe that we have successfully developed a new cost-effective, one-piece biosensor and, with this study, we have demonstrated improvement in the accuracy of our Symphony system glucose readings. Data from this study demonstrates that Symphony, using the new, improved, cost-effective biosensor, is safe, accurate and reliable at monitoring glucose levels. We look forward to continued progress with our Symphony development program throughout this year and next as we move toward our goal of making Symphony available to patients.”
About QualityStocks:
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net
Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
